Company facts
- Headquarters
- Boston, Massachusetts
- Most recent report
- 8-K, filed Nov 3, 2026
- Incorporated
- Delaware
- Filings on record
- 30 filings
- On EDGAR
- CIK 2044950
- Fiscal year ends
- December
- Filer status
- N/A
News 1
Prospectuses and Registrations 4
Ownership 8 of 16
- SCHEDULE 13D Large holder reported an active stake Nov 6, 2026
- SCHEDULE 13G Large holder reported a passive stake Nov 5, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 2, 2026
- 4 Insider reported a trade Nov 2, 2026
- 4 Insider reported a trade Nov 2, 2026
- 4 Insider reported a trade Nov 2, 2026
- 3 Insider reported their initial holding Oct 29, 2026
Other 8 of 9
- EFFECT Notice that a registration became effective Oct 29, 2026
- S-1MEF Oct 29, 2026
- CERT Exchange certified a listing Oct 29, 2026
- 8-A12B Registration of a security for exchange listing Oct 27, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Sep 15, 2026
- DRS Draft registration statement, submitted confidentially Aug 3, 2026
- D Feb 26, 2025
- D Jan 8, 2025
Everything here comes from Bambusa Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.